Investigating the Effect of Itraconazole on the Pharmacokinetics of AZD4144 in Healthy Participants
← catalyst calendarNCT07685600 · readout in 70 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
32estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-30 | estimated | When the study began enrolling |
| Primary completion | 2026-10-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-10-28 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy
Interventions
- Drug: AZD4144
- Drug: AZD4144
- Drug: Itraconazole
Primary outcomes
what the primary-completion date above is the date OFArea under concentration time curve from time 0 to infinity (AUCinf)
measured Period 1: Day 1 to Day 6; Period 3: Day 10 to Day 16
Area under concentration curve from time 0 to the last quantifiable concentration (AUClast)
measured Period 1: Day 1 to Day 6; Period 3: Day 10 to Day 16
Maximum observed drug concentration (Cmax)
measured Period 1: Day 1 to Day 6; Period 3: Day 10 to Day 16
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed